Safety and efficacy of ET-743: The French experience

Initial evidence of clinical benefit with ecteinascidin-743 (ET-743) in patients with sarcoma was provided during a Phase I pharmacokinetic study in which 52 patients received ET-743 at doses of 50-1800 micrograms/m2 as a 24 h continuous infusion every 3 weeks. Neutropenia and thrombocytopenia were...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anti-cancer drugs 2002-05, Vol.13 Suppl 1, p.S11-S14
1. Verfasser:	Brain, Etienne GC
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - adverse effects Antineoplastic Agents, Alkylating - pharmacokinetics Antineoplastic Agents, Alkylating - therapeutic use Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Dioxoles - administration & dosage Dioxoles - adverse effects Dioxoles - pharmacokinetics Dioxoles - therapeutic use Disease-Free Survival Drug Administration Schedule France Humans Infusions, Intravenous Isoquinolines - administration & dosage Isoquinolines - adverse effects Isoquinolines - pharmacokinetics Isoquinolines - therapeutic use Multicenter Studies as Topic Sarcoma - drug therapy Sarcoma - mortality Sarcoma - pathology Survival Analysis Tetrahydroisoquinolines Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!